Granulocyte-macrophage colony-stimulating factor-associated histiocytosis and capillary-leak syndrome following autologous bone marrow transplantation: Two case reports and a review of the literature

Bone Marrow Transplantation

Volumn 21, Issue 2, 1998, Pages 209-214

  Al Homaidhi, A ^a   Prince, H M ^a,b   Al Zahrani, H ^a   Doucette, D ^a   Keating, A ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Capillary leak syndrome; GM CSF; Histiocytosis; Transplantation

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CAPILLARY LEAK SYNDROME; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTIOCYTOSIS; HODGKIN DISEASE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0031962601     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701036     Document Type: Article

References (36)

1. Metcalf D. The granulocyte-macrophage colony simulating factors. Science 1985; 229: 16-12.
2. Brandt SJ, Peters WP, Atwater SK et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on haemopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. New Engl J Med 1988; 318: 869-876.
3. Herrman F, Schultz G, Wieser M. Effect of granulocyte-macrophage colony stimulating factors on neutropenia and related morbidity induced by myelotoxic chemotherapy. Am J Med 1990; 88: 619-624.
4. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Engl J Med 1991; 324: 1773-1778.
5. Lieschke GJ, Maher D, Cebon J et al. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Ann Int Med 1989; 110: 357-364.
6. Lieschke GJ, Maher D, O'Connor M et al. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res 1990; 50: 606-614.
7. Steward WP, Scarffe JH, Austin R et al. Recombinant human granulocyte-macrophage colony-stimulating factor given as daily short infusions - a phase I dose toxicity study. Br J Cancer 1989; 59: 142-145.
8. Groopman JE, Mitsuyasu RT, DeLeo MJ et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. New Engl J Med 1987; 317: 593-598.
9. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (second of two parts). New Engl J Med 1992; 327: 99-106.
10. Prince HM, Cheng M, Cameron RG et al. Severe hepatotoxicity from granulocyte-macrophage colony-stimulating factor administered after autologous bone marrow transplantation. Bone Marrow Transplant 1995; 16: 195-197.
11. Cahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 1996; 18: 177-184.
12. McDonald GB, Shulman HM, Wolford JL et al. Liver disease after human marrow transplantation. Semin Liver Dis 1987; 7: 210-229.
13. Emminger W, Emminger-Schmidmeier W, Peters C et al. Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor treatment of a patient in a continuous febrile state. Blut 1990; 61: 219-221.
14. Arning M, Kliche KO, Schneider W. GM-CSF and capillary leak syndrome. Ann Hematol 1991; 62: 83.
15. Bodey GP, Anaissie E, Gutterman J el al. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993; 17: 705-707.
16. Herberman RB, Interleukin-2 therapy in human cancer. J Clin Oncol 1989; 7: 1-4.
17. Klausmann M, Pfluger KH, Krumwieh D et al. Modulation of functions of granulocytes by recombinant human GM-CSF and possible complications of GM-CSF therapy. Leukemia 1988; 2: (Suppl.): 63S-72S.
18. Sisson SD, Dinarello CA. Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood 1988; 72: 1368-1374.
19. Sozinski MA, Cannistra SA, Sullivan R et al. Granulocyte-macrophage colony-stimulating factor induces the expression of CD 11b surface adhesion molecule on human granulocytes in vivo. Blood 1988; 72: 691-697.
20. Wing EJ, Magee DM, Whiteside TL et al. Recombinant human granulocyte-macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood 1989; 73: 643-646.
21. Wong KF, Chan KC, Hemophagocytic disorders - a review. Hematol Rev 1991; 5: 5-37.
22. Wilson PA, Ayscue LH, Jones GR et al. Bone marrow histiocytic proliferation with colony-stimulating factor therapy. Am J Clin Pathol 1993; 99: 311-313.
23. Lang E, Cibull ML, Gallichio VS et al. Proliferation of abnormal bone marrow histiocytes, an undesired effect of GM-CSF therapy in a patient with Hurlers syndrome undergoing bone marrow transplantation. Am J Hematol 1992; 41: 280-284.
24. Rosenthal NS, Farhi DC. Failure to engraft after bone marrow transplantation: bone marrow morphologic findings. Am J Clin Pathol 1994; 102: 821-824.
25. Risti B, Flury RF, Schaffiner A. Fatal hematophagic histiocytosis after GM-CSF and chamotherapy for high-grade malignant lymphoma. Clin Invest 1994; 72: 457-461.
26. Urabe A. Colony-stimulating factor and macrophage proliferation. Am J Clin Pathol 1994; 101: 116.
27. Lang RA, Metcalf D, Cuthbertson RA et al. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness and a fatal syndrome of tissue damage. Cell 1987: 51: 657-686.
28. Gallichio VS, Hughes NR, Lang E et al. Synergistic action of IL-1, IL-6, and B-FGF on abnormal bone marrow histiocytes in a patient with Hurlers syndrome receiving GM-CSF therapy undergoing bone marrow transplantation. J Cell Biochem 1992; 16A: D205.
29. Chen BDM, Mueller M, Chou TH, Role of granulocyte/macrophage colony-stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation. J Immunol 1988; 141: 139-144.
30. Coleman DL, Chodakewitz JA, Bartiss AH et al. Granulocyte-macrophage colony stimulating factor enhances selective effector functions of tissue-derived macrophages. Blood 1988; 72: 573-678.
31. Heidenreich S, Gong JH, Schmidt A et al. Macrophage activation by granulocyte/macrophage colony-stimulating factor. Priming for enhanced release of tumor necrosis factor alpha and prostoglandin E2. J Immunol 1989; 143: 1198-1205.
32. Metcalf D, Begley CG, Williamson DJ et al. Hemopoietic responses in mice injected with purified injected GM-CSF. Exp Hematol 1987; 15: 1-9.
33. Simms HH, Gaither TA, Fries LF et al. Monokines released during short-term Fc receptor phagocytosis up-regulate polymorphonuclear leukocytes and monocyte-phagocytic function. J Immunol 1991; 147: 265-272.
34. Foucar K. Bone marrow histiocytosis and autologous graft failure: possible implications. Am J Clin Pathol 1994; 102: 713-714.
35. Al-Fiar F, Prince HM, Imrie K et al. Bone marrow mononuclear cell count does not predict neutrophil and platelet recovery following autologous bone marrow transplant; value of the colony-forming unit granulocyte-macrophage (CFU-GM) assay. Cell Transplant 1997; 6: 491-495.
36. Gulati SC, Bennett CL. Granulocyte-macrophage colony-simulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin's disease. Ann Intern Med 1992; 116: 177-182.